OPKO Health, Inc. (0KCS.L)
USD 1.78
(2.89%)
USD 1.78
(2.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 230.68 Million USD | 282.56% |
| 2022 | 60.3 Million USD | 13.35% |
| 2021 | 53.2 Million USD | -64.48% |
| 2020 | 149.78 Million USD | 19.12% |
| 2019 | 125.74 Million USD | 293.84% |
| 2018 | -64.87 Million USD | -197.57% |
| 2017 | 66.49 Million USD | 153.18% |
| 2016 | -125.03 Million USD | 13.29% |
| 2015 | -144.2 Million USD | -516.76% |
| 2014 | 34.6 Million USD | -17.51% |
| 2013 | 41.94 Million USD | 995.33% |
| 2012 | -4.68 Million USD | 92.53% |
| 2011 | -62.75 Million USD | -1786.92% |
| 2010 | -3.32 Million USD | 85.54% |
| 2009 | -22.99 Million USD | -535.04% |
| 2008 | 5.28 Million USD | 157.85% |
| 2007 | -9.13 Million USD | -6.31% |
| 2006 | -8.59 Million USD | 3.43% |
| 2005 | -8.9 Million USD | -1.91% |
| 2004 | -8.73 Million USD | 13.8% |
| 2003 | -10.13 Million USD | -69.26% |
| 2002 | -5.98 Million USD | 59.53% |
| 2001 | -14.79 Million USD | 58.07% |
| 2000 | -35.28 Million USD | -1046.3% |
| 1999 | -3.07 Million USD | 53.36% |
| 1998 | -6.6 Million USD | -288.24% |
| 1997 | -1.7 Million USD | 41.38% |
| 1996 | -2.9 Million USD | 46.3% |
| 1995 | -5.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 228.87 Million USD | -33.46% |
| 2024 Q1 | 343.93 Million USD | 49.1% |
| 2023 Q3 | 74.7 Million USD | -60.17% |
| 2023 Q1 | 100.5 Million USD | 66.67% |
| 2023 Q4 | 230.68 Million USD | 208.81% |
| 2023 Q2 | 187.56 Million USD | 86.63% |
| 2023 FY | 230.68 Million USD | 282.56% |
| 2022 Q1 | 177.22 Million USD | 233.13% |
| 2022 Q4 | 60.3 Million USD | -45.87% |
| 2022 FY | 60.3 Million USD | 13.35% |
| 2022 Q3 | 111.39 Million USD | 54.93% |
| 2022 Q2 | 71.89 Million USD | -59.43% |
| 2021 Q1 | 203.91 Million USD | 36.13% |
| 2021 FY | 53.2 Million USD | -64.48% |
| 2021 Q2 | 184.72 Million USD | -9.41% |
| 2021 Q4 | 53.2 Million USD | -44.41% |
| 2021 Q3 | 95.69 Million USD | -48.19% |
| 2020 Q2 | 309.45 Million USD | 10.06% |
| 2020 Q3 | 241.79 Million USD | -21.86% |
| 2020 Q4 | 149.78 Million USD | -38.05% |
| 2020 FY | 149.78 Million USD | 19.12% |
| 2020 Q1 | 281.16 Million USD | 123.59% |
| 2019 Q4 | 125.74 Million USD | -49.6% |
| 2019 Q3 | 249.49 Million USD | 16.79% |
| 2019 Q2 | 213.63 Million USD | 6117.8% |
| 2019 FY | 125.74 Million USD | 293.84% |
| 2019 Q1 | -3.55 Million USD | 94.53% |
| 2018 Q3 | 165.03 Million USD | 27.57% |
| 2018 FY | -64.87 Million USD | -197.57% |
| 2018 Q4 | -64.87 Million USD | -139.31% |
| 2018 Q2 | 129.36 Million USD | 959.99% |
| 2018 Q1 | -15.04 Million USD | -122.62% |
| 2017 Q2 | 1.93 Million USD | 106.98% |
| 2017 Q1 | -27.72 Million USD | 77.83% |
| 2017 Q3 | 50.73 Million USD | 2520.4% |
| 2017 FY | 66.49 Million USD | 153.18% |
| 2017 Q4 | 66.49 Million USD | 31.07% |
| 2016 Q2 | -46.94 Million USD | -87.37% |
| 2016 FY | -125.03 Million USD | 13.29% |
| 2016 Q3 | -93.14 Million USD | -98.42% |
| 2016 Q4 | -125.03 Million USD | -34.23% |
| 2016 Q1 | -25.05 Million USD | 82.63% |
| 2015 Q2 | -95.26 Million USD | 57.8% |
| 2015 Q1 | -225.73 Million USD | -752.4% |
| 2015 Q3 | -66.79 Million USD | 29.89% |
| 2015 Q4 | -144.2 Million USD | -115.9% |
| 2015 FY | -144.2 Million USD | -516.76% |
| 2014 FY | 34.6 Million USD | -17.51% |
| 2014 Q1 | 82.53 Million USD | 96.77% |
| 2014 Q2 | -300 Thousand USD | -100.36% |
| 2014 Q4 | 34.6 Million USD | 195.78% |
| 2014 Q3 | 11.69 Million USD | 3999.33% |
| 2013 FY | 41.94 Million USD | 995.33% |
| 2013 Q2 | 89.87 Million USD | 131.67% |
| 2013 Q1 | 38.79 Million USD | 928.07% |
| 2013 Q3 | 70.91 Million USD | -21.1% |
| 2013 Q4 | 41.94 Million USD | -40.85% |
| 2012 Q3 | -2.06 Million USD | 91.25% |
| 2012 Q1 | -32.92 Million USD | 47.54% |
| 2012 FY | -4.68 Million USD | 92.53% |
| 2012 Q2 | -23.6 Million USD | 28.32% |
| 2012 Q4 | -4.68 Million USD | -126.77% |
| 2011 FY | -62.75 Million USD | -1786.92% |
| 2011 Q4 | -62.75 Million USD | -80.92% |
| 2011 Q3 | -34.68 Million USD | -43.07% |
| 2011 Q2 | -24.24 Million USD | 27.25% |
| 2011 Q1 | -33.32 Million USD | -902.01% |
| 2010 Q3 | -6.61 Million USD | -84.93% |
| 2010 Q2 | -3.57 Million USD | 78.94% |
| 2010 Q1 | -16.98 Million USD | 26.14% |
| 2010 Q4 | -3.32 Million USD | 49.71% |
| 2010 FY | -3.32 Million USD | 85.54% |
| 2009 Q2 | -21.35 Million USD | -240.87% |
| 2009 Q3 | -43.45 Million USD | -103.44% |
| 2009 Q4 | -22.99 Million USD | 47.08% |
| 2009 FY | -22.99 Million USD | -535.04% |
| 2009 Q1 | 15.16 Million USD | 186.83% |
| 2008 Q1 | -941 Thousand USD | 89.7% |
| 2008 Q2 | 6.37 Million USD | 777.15% |
| 2008 Q4 | 5.28 Million USD | 301.68% |
| 2008 FY | 5.28 Million USD | 157.85% |
| 2008 Q3 | -2.62 Million USD | -141.13% |
| 2007 Q1 | -9.65 Million USD | -12.28% |
| 2007 Q4 | -9.13 Million USD | -245.35% |
| 2007 FY | -9.13 Million USD | -6.31% |
| 2007 Q3 | 6.28 Million USD | 381.76% |
| 2007 Q2 | 1.3 Million USD | 113.52% |
| 2006 Q4 | -8.59 Million USD | -0.06% |
| 2006 Q1 | -8.85 Million USD | 0.56% |
| 2006 FY | -8.59 Million USD | 3.43% |
| 2006 Q2 | -8.8 Million USD | 0.52% |
| 2006 Q3 | -8.59 Million USD | 2.43% |
| 2005 Q1 | -8.4 Million USD | 3.72% |
| 2005 FY | -8.9 Million USD | -1.91% |
| 2005 Q4 | -8.9 Million USD | 0.59% |
| 2005 Q3 | -8.95 Million USD | -10.31% |
| 2005 Q2 | -8.11 Million USD | 3.47% |
| 2004 Q1 | -9.4 Million USD | 7.18% |
| 2004 Q2 | -9.18 Million USD | 2.35% |
| 2004 Q4 | -8.73 Million USD | 3.36% |
| 2004 FY | -8.73 Million USD | 13.8% |
| 2004 Q3 | -9.03 Million USD | 1.59% |
| 2003 FY | -10.13 Million USD | -69.26% |
| 2003 Q3 | -10.91 Million USD | 18.12% |
| 2003 Q1 | -14.74 Million USD | -146.36% |
| 2003 Q4 | -10.13 Million USD | 7.18% |
| 2003 Q2 | -13.33 Million USD | 9.6% |
| 2002 Q4 | -5.98 Million USD | 35.21% |
| 2002 FY | -5.98 Million USD | 59.53% |
| 2002 Q1 | -13.48 Million USD | 8.81% |
| 2002 Q2 | -11.38 Million USD | 15.63% |
| 2002 Q3 | -9.23 Million USD | 18.82% |
| 2001 FY | -14.79 Million USD | 58.07% |
| 2001 Q4 | -14.79 Million USD | 22.7% |
| 2001 Q3 | -19.13 Million USD | -94.88% |
| 2001 Q2 | -9.82 Million USD | 70.23% |
| 2001 Q1 | -32.98 Million USD | 6.51% |
| 2000 Q2 | -38.67 Million USD | -136.2% |
| 2000 Q3 | -36.47 Million USD | 5.7% |
| 2000 Q4 | -35.28 Million USD | 3.26% |
| 2000 FY | -35.28 Million USD | -1046.3% |
| 2000 Q1 | -16.37 Million USD | -431.97% |
| 1999 Q2 | -4.7 Million USD | 7.84% |
| 1999 Q4 | -3.07 Million USD | 26.71% |
| 1999 FY | -3.07 Million USD | 53.36% |
| 1999 Q1 | -5.1 Million USD | 22.73% |
| 1999 Q3 | -4.2 Million USD | 10.64% |
| 1998 Q4 | -6.6 Million USD | 15.38% |
| 1998 FY | -6.6 Million USD | -288.24% |
| 1998 Q1 | -1.1 Million USD | 35.29% |
| 1998 Q2 | -8.9 Million USD | -709.09% |
| 1998 Q3 | -7.8 Million USD | 12.36% |
| 1997 Q2 | -1.9 Million USD | 29.63% |
| 1997 Q1 | -2.7 Million USD | 6.9% |
| 1997 Q3 | -1.2 Million USD | 36.84% |
| 1997 FY | -1.7 Million USD | 41.38% |
| 1997 Q4 | -1.7 Million USD | -41.67% |
| 1996 Q3 | -3.7 Million USD | 13.95% |
| 1996 Q4 | -2.9 Million USD | 21.62% |
| 1996 Q2 | -4.3 Million USD | 12.24% |
| 1996 Q1 | -4.9 Million USD | 0.0% |
| 1996 FY | -2.9 Million USD | 46.3% |
| 1995 FY | -5.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 324.071% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 2390.567% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 838.966% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 85.449% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -16.468% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 252.746% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -623.484% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 39.093% |
| bluebird bio, Inc. | 108.57 Million USD | -112.472% |
| Blueprint Medicines Corporation | 702.83 Million USD | 67.178% |
| Adicet Bio, Inc. | -142 Million USD | 262.444% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 270.371% |
| Dynavax Technologies Corporation | 106.63 Million USD | -116.33% |
| Editas Medicine, Inc. | -87.11 Million USD | 364.8% |
| FibroGen, Inc. | 56.76 Million USD | -306.368% |
| Geron Corporation | 14.76 Million USD | -1462.787% |
| Illumina, Inc. | 1.21 Billion USD | 80.998% |
| Insmed Incorporated | 721.62 Million USD | 68.033% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 307.073% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 78.119% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 98.205% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 89.004% |
| Evolus, Inc. | 63.7 Million USD | -262.094% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -30.109% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 76.178% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 788.051% |
| Verastem, Inc. | -37.27 Million USD | 718.818% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 97.199% |
| Zoetis Inc. | 4.76 Billion USD | 95.156% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.141% |
| Biogen Inc. | 6.28 Billion USD | 96.332% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 3349.056% |
| Perrigo Company plc | 3.32 Billion USD | 93.056% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 79.853% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 302.553% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2658.596% |
| Myriad Genetics, Inc. | 88.1 Million USD | -161.842% |
| Waters Corporation | 1.96 Billion USD | 88.233% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 726.788% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1683.057% |
| Nektar Therapeutics | 210.24 Million USD | -9.724% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 525.175% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -3109.726% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 215.445% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -59.008% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.412% |
| Imunon, Inc. | -4.69 Million USD | 5008.908% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -3210.57% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 49.709% |
| Homology Medicines, Inc. | 18.43 Million USD | -1151.196% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 951.229% |
| Exelixis, Inc. | -73.05 Million USD | 415.788% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 83.294% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1191.474% |
| Incyte Corporation | -3.17 Billion USD | 107.265% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 69.877% |